Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma

Pang, Xin; Fan, Hao; Tang, Yaling; Wang, Shasha; Cao, Mingxin; Wang, Haofan; Dai, Lu‐ling; Wang, Ke; Yu, Xixun; Wu, Jing‐biao; Tang, Ya‐Jie; Liang, Xin‐hua

doi:10.1371/journal.pone.0229089

Cited by 49 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MDSCs possess a strong immunomodulatory capacity, being recruited during inflammatory/infectious processes [31]. In the oral mucosa, MDSCs have mainly been studied in relation to oral squamous cell carcinomas, as they facilitate cancer growth and immune evasion by suppressing T cells [32][33][34]. MDSCs are related to resident macrophages and can actually differentiate into macrophages [31].…”

Section: Tolerance Mediated By Dendritic Cellsmentioning

confidence: 99%

Immune Tolerance in the Oral Mucosa

Pelaez-Prestel

Sanchez-Trincado

Lafuente

et al. 2021

IJMS

View full text Add to dashboard Cite

The oral mucosa is a site of intense immune activity, where a large variety of immune cells meet to provide a first line of defense against pathogenic organisms. Interestingly, the oral mucosa is exposed to a plethora of antigens from food and commensal bacteria that must be tolerated. The mechanisms that enable this tolerance are not yet fully defined. Many works have focused on active immune mechanisms involving dendritic and regulatory T cells. However, epithelial cells also make a major contribution to tolerance by influencing both innate and adaptive immunity. Therefore, the tolerogenic mechanisms concurring in the oral mucosa are intertwined. Here, we review them systematically, paying special attention to the role of oral epithelial cells.

show abstract

Section: Tolerance Mediated By Dendritic Cellsmentioning

confidence: 99%

Immune Tolerance in the Oral Mucosa

Pelaez-Prestel

Sanchez-Trincado

Lafuente

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Consistent with this, Ren et al have indicated that early-stage MDSCs of peripheral blood and tumor-infiltrating early-stage MDSCs can upregulate arginase-1 [ 40 ]. Besides, the co-culture of MDSCs with tumoral cells can upregulate arginase-1 expression in MDSCs [ 41 ]. Although the exact mechanism of TIGIT and PD-1 co-expression has not been exactly identified in tumors, the currently available evidence indicates that TIGIT and PD-1 can both increase arginase-1 activity, which can ultimately lead to T cells anergy and the development of immunosuppressive tumor microenvironment.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers

Hosseinkhani

Baradaran

Jafarabadi

et al. 2021

IJMS

View full text Add to dashboard Cite

Preclinical studies have indicated that T-cell immunoglobulin and ITIM domain (TIGIT) can substantially attenuate anti-tumoral immune responses. Although multiple clinical studies have evaluated the significance of TIGIT in patients with solid cancers, their results remain inconclusive. Thus, we conducted the current systematic review and meta-analysis based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) to determine its significance in patients with solid cancers. We systematically searched the Web of Science, Embase, PubMed, and Scopus databases to obtain peer-reviewed studies published before September 20, 2020. Our results have shown that increased TIGIT expression has been significantly associated with inferior overall survival (OS) (HR = 1.42, 95% CI: 1.11–1.82, and p-value = 0.01). Besides, the level of tumor-infiltrating TIGIT+CD8+ T-cells have been remarkably associated inferior OS and relapse-free survival (RFS) of affected patients (HR = 2.17, 95% CI: 1.43–3.29, and p-value < 0.001, and HR = 1.89, 95% CI: 1.36–2.63, and p-value < 0.001, respectively). Also, there is a strong positive association between TIGIT expression with programmed cell death-1 (PD-1) expression in these patients (OR = 1.71, 95% CI: 1.10–2.68, and p-value = 0.02). In summary, increased TIGIT expression and increased infiltration of TIGIT+CD8+ T-cells can substantially worsen the prognosis of patients with solid cancers. Besides, concerning the observed strong association between TIGIT and PD-1, ongoing clinical trials, and promising preclinical results, PD-1/TIGIT dual blockade can potentially help overcome the immune-resistance state seen following monotherapy with a single immune checkpoint inhibitor in patients with solid cancers.

show abstract

“…Recently, Pang et al . reported that the MDSCs number was increased in the tissue of oral squamous cell carcinoma (OSCC) patients, which was positively associated with lymph node metastasis, pathological grade, T stage, and poor prognosis [ 14 ]. In a prospective cohort study, Kim et al .…”

Section: Immune Response In Head and Neck Cancermentioning

confidence: 99%

A review on the advances and challenges of immunotherapy for head and neck cancer

et al. 2021

View full text Add to dashboard Cite

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide. Due to the interaction of tumor cells with immune cells in the tumor microenvironment, immunotherapy of HNCs, along with traditional treatments such as chemotherapy, radiotherapy, and surgery, has attracted much attention. Four main immunotherapy strategies in HNCs have been developed, including oncolytic viruses, monoclonal antibodies, chimeric antigen receptor T cells (CAR-T cells), and therapeutic vaccines. Oncorine (H101), an approved oncolytic adenovirus in China, is the pioneer of immunotherapy for the treatment of HNCs. Pembrolizumab and nivolumab are mAbs against PD-L1 that have been approved for recurrent and metastatic HNC patients. To date, several clinical trials using immunotherapy agents and their combination are under investigation. In this review, we summarize current the interaction of tumor cells with immune cells in the tumor microenvironment of HNCs, the main strategies that have been applied for immunotherapy of HNCs, obstacles that hinder the success of immunotherapies in patients with HNCs, as well as solutions for overcoming the challenges to enhance the response of HNCs to immunotherapies.

show abstract

Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma

Cited by 49 publications

References 50 publications

Immune Tolerance in the Oral Mucosa

Immune Tolerance in the Oral Mucosa

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers

A review on the advances and challenges of immunotherapy for head and neck cancer

Contact Info

Product

Resources

About